Annexin appoints Jamal El-Mosleh as new CEO
Annexin Pharmaceuticals has appointed Jamal El-Mosleh as new CEO of the company, and he started his new position on October 16th.
Jamal El-Mosleh has a MSc in Industrial Economics with focus on biotechnology from the Chalmers University of Technology and a Master from Chalmers School of Entrepreneurship (Biotechnology). He has previously had a position as CEO for Immunicum, where he worked 2007-2016. He was a driving force in Immunicum's entry on the stock exchange and he took the company's leading product candidate from idea to an extensive international clinical program with several indications.
Annexin Pharmaceuticals has appointed Jamal El-Mosleh as new CEO of the company, and he started his new position on October 16th.
Jamal El-Mosleh has a MSc in Industrial Economics with focus on biotechnology from the Chalmers University of Technology and a Master from Chalmers School of Entrepreneurship (Biotechnology). He has previously had a position as CEO for Immunicum, where he worked 2007-2016. He was a driving force in Immunicum’s entry on the stock exchange and he took the company’s leading product candidate from idea to an extensive international clinical program with several indications.
Published: October 17, 2017
